Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06251934 · ClinicalTrials.gov registry record
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 785
- Enrollment target
NCT06251934 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 785 participants.
The verdict
NCT06251934 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 785 participants
- Enrollment target
Study Summary
This was a retrospective, longitudinal, observational study conducted using the Flatiron Health electronic health record (EHR)-derived database. BRAF+ advanced or metastatic (i.e., stage III or IV) melanoma patients treated at oncology practices across the US were identified for potential inclusion. All included patients were aged ≥18 years and required to have a diagnosis of melanoma (International Classification of Diseases (ICD)-9 172.x \& ICD-10 C43 or D03x), a pathologic unresectable stage III or IV diagnosis, subsequent first-line (1L) treatment with either immunotherapy (IO) (nivolumab, pembrolizumab, ipilimumab + nivolumab) or targeted therapy (TT) dafratenib + trametinib (dab/tram) on or after 01 January 2014, and evidence of a BRAF-positive result at any point in time.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 785 participants |
| Start Date | 2022-09-28 |
| Est. Completion | 2022-11-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06251934
The ClinicalTrials.gov registry entry for NCT06251934 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 785 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06251934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06251934 about?
NCT06251934 is a clinical study titled "Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma". This was a retrospective, longitudinal, observational study conducted using the Flatiron Health electronic health record (EHR)-derived database. BRAF+ advanced or metastatic (i.e., stage III or IV) melanoma patients treated at oncology practices across the US were identified for potential inclusion....
What is the current status of trial NCT06251934?
This trial is currently completed. The enrollment target is 785 participants. The study started on 2022-09-28. Estimated completion is 2022-11-24.
Who is sponsoring clinical trial NCT06251934?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.